Tenaya Therapeutics Reports Third-Quarter 2026 Results and Business Update
Tenaya Therapeutics said it received FDA Regenerative Medicine Advanced Therapy designation for TN-401.
Related stories
MetLife Q3 Net Income Rises to $2.397 Billion
MetLife reported third-quarter 2026 net income of $2.397 billion, up from $896 million a year earlier, alongside revenue growth.
M impact | EQUITY | Nov 04, 2026, 10:11 PM UTC
Great Elm Group Q1 Revenue Drops on Property Sale Timing
Great Elm Group reported lower Q1 revenue, citing the timing of property sales.
M impact | EQUITY | Nov 04, 2026, 10:09 PM UTC
Vaxcyte Q3 Loss Smaller Than Estimates; Plans VAX-31 Filing in H1 2028
Vaxcyte reported a Q3 loss smaller than estimates and plans to file VAX-31 in the first half of 2028.
M impact | EQUITY | Nov 04, 2026, 10:09 PM UTC
Mercado Libre Q3 Revenue and Financial Income Rise 45% to $10.75 Billion
Mercado Libre reported third-quarter net revenue and financial income of $10.75 billion, up 45% year over year. Brazil delivered the strongest growth.
M impact | EQUITY | Nov 04, 2026, 10:09 PM UTC
Genworth Financial Posts Q3 Net Loss on Closed Block Weakness
Genworth Financial reported a third-quarter net loss, citing weakness in its Closed Block segment.
M impact | EQUITY | Nov 04, 2026, 10:08 PM UTC
B2Gold Reports Q3 Results, Lowers Annual AISC Guidance
B2Gold lowered its annual all-in sustaining cost guidance and said it remains on track to achieve production guidance.
M impact | EQUITY | Nov 04, 2026, 10:08 PM UTC